Do you want to read an article? Please log in or register.
Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond
Skin Cancer
Related content
Skin Cancer
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study
Int J Cancer
Gutzmer R, Weichenthal M, Eigentler T, Mohr P, Sickmann T, Dücker P, Gebhardt C, Haferkamp S, Kähler KC, Meier F, Pföhler C, Sindrilaru A, Terheyden P, von Wasielewski I, Ugurel S, Ulrich J, Utikal J, Weishaupt C, Schadendorf D
doi: 10.1002/ijc.70440
Skin Cancer
Dual checkpoint blockade beyond clinical trials: Real-world experience with nivolumab-relatlimab in advanced melanoma
Eur J Cancer
Asher N, Avner M, Goldberg N, Markel G, Israei-Weller N, Dokhan R, Lev-Ari S, Grynberg S, Bar-Sela G, Wainstein E, Yakobson A, Miodovnik M, Kozlener E, Rasco AF, Lotem M
doi: 10.1016/j.ejca.2026.117047
Lung, Respiratory and Thoracic Cancer
Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England
Lung Cancer
Karim N, Arnold K, Summers Y, Akram T, Trankov N, Vladimirova A, Chopra D, Mesa-Frias M, Waterhouse D, Stollenwerk B
doi: 10.1016/j.lungcan.2026.109469
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
ESMO Open
Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV
doi: 10.1016/j.esmoop.2025.106031
Multiple Myeloma (MM)
Real-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma initiating their second, third, and fourth lines of treatment: data from the US Flatiron database
Leuk Lymphoma
Nieto MJ, Shih YH, Fang J, Qiu Y, Gentili C, Hernandez Rivera G
doi: 10.1080/10428194.2026.2702128
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Adv Ther
Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Pérol M
doi: 10.1007/s12325-025-03465-4
Lung, Respiratory and Thoracic Cancer
Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study
Lung Cancer
Assié JB, Greillier L, Gobert A, Falchero L, Thibonnier L, Chasseray M, Raynaud C, Picchi H, Chatellier T, Corre R, Molinier O, Bakebe A, Naltet C, Quillot FM, Gavoille L, Pierret T, Dot JM, Wislez M, Sabatini M, Tiercin M, Zalcman G, Cassuto O, Largillier R, Madroszyk A, Munsch N, Pichon E, Ricordel C, Bylicki O, GFPC
doi: 10.1016/j.lungcan.2026.109622
Lung, Respiratory and Thoracic Cancer
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study
Lung Cancer
Gomez-Randulfe I, Monaca F, Cantale O, Reale ML, Mrak L, Zullo L, Diaz SS, Bueno MZ, Maridueña Moreno MA, Davis C, Cox S, Lee D, Shah R, Geldart T, Baena J, Benitez JC, Rosario Garcia Campelo MA, Remon J, Planchard D, Galetta D, Tiseo M, Cortinovis D, Metro G, Bria E, Passiglia F, Novello S, Califano R
doi: 10.1016/j.lungcan.2025.108797
Lung, Respiratory and Thoracic Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z